The United States Court of Appeals for the Fifth Circuit has remanded a court case involving access to Mifepristone back to the district in which the case began.
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...
HotCopper.com on MSN3h
Neurotech knocked back by FDA as agency declares target condition not rare enough for special statusNeurotech International (NTI) has flagged to its shareholders that the FDA hasn’t granted its product NTI164 orphan drug ...
A Colorado-based candy shop issued a recall after discovering one of its products caused an allergic reaction. The Food and ...
The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...
FARGO — A new FDA approved drug, to help people with schizophrenia, will soon be accessible for medical officials to ...
Baxter International said it would temporarily close production at its North Cove, North Carolina-based facility, raising ...
Inquirer on MSN5h
Public warned vs fake pain reliever laced with deadly drugThe Food and Drug Administration (FDA) has warned the public to watch out for fake versions of a US-made pain reliever which ...
Some of the foods you and your family could be eating contain ingredients banned in other countries but still legal here in ...
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...
Amphix Bio earned FDA breakthrough device designation for a bone regeneration drug-device combination, according to an Oct. 3 news release.
Dry eye disease affects up to 15% of the U.S. population and is one of the largest markets in the ophthalmology field.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback